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Pancreatic  exocrine  insufﬁciency  is  a well-documented  complication  of  chronic  pancreatitis;  however,
study  results  of  pancreatic  exocrine  insufﬁciency  in pancreatic  cancer  are  less  consistent.  This  applies  forvailable online 6 July 2015
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patients who  are  treated  non-surgically  and  those  who  undergo  curative  pancreatic  cancer  resection.
This review  article  summarizes  relevant  studies  addressing  pancreatic  exocrine  insufﬁciency  in pan-
creatic  cancer,  with  particular  differentiation  between  non-surgically  and  surgically  treated  patients,
as  well  as between  the  different  surgeries.  We  also  summarize  studies  addressing  pancreatic  enzyme
replacement  therapy  in  pancreatic  cancer.
© 2015  Editrice  Gastroenterologica  Italiana  S.r.l.  Published  by Elsevier  Ltd.  All  rights  reserved.. Introduction
Pancreatic exocrine insufﬁciency (PEI) is a known complication
f both benign and malignant pancreatic diseases, pancreatic resec-
ion, and post-surgical alteration of the anatomy of the foregut. It
s deﬁned as inadequate pancreatic enzyme activity for digestion
aused by insufﬁcient pancreatic enzyme production, insufﬁcient
ctivation, or disturbed enzyme deactivation [1].
.1. Physiology of pancreatic enzyme release
Pancreatic enzyme release occurs in response to nutritional
ntake. The initial stimulus is seeing, smelling, and tasting of food
hich is vagal mediated and termed cephalic phase [2]. Next,
astric distension increases pancreatic enzyme secretion via the
astro-pancreatic reﬂex (gastric phase) [2,3]. The passage of chyme
hrough the duodenum provides the most robust stimulation of
xocrine pancreatic secretion, particularly the passage of hydrol-
sed triglycerides (free fatty acids). This is termed intestinal phase
nd is mostly cholecystokinin (CCK) mediated [4–6].Following duodenal nutrient exposure in healthy volunteers,
ancreatic lipase secretion peaks within 30 min  at a fourfold higher
evel than its baseline and decreases to its baseline over 2–4 h in a
∗ Corresponding author at: Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL
2224, United States. Tel.: +1 904 953 6982; fax: +1 904 953 6225.
E-mail address: Raimondo.Massimo@mayo.edu (M.  Raimondo).
ttp://dx.doi.org/10.1016/j.dld.2015.06.015
590-8658/© 2015 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. Allbiphasic manner. Similar patterns were also found for amylase and
trypsin [7–10].
Ultimately, pancreatic exocrine function is inhibited by a phys-
iological feedback mechanism when nutrients reach the distal
ileum. In this context, ileal lipid perfusion in 12 healthy volun-
teers resulted in dose-dependent inhibition of both pancreatic
enzyme and bile secretion with unchanged intestinal motor activity
[7,11,12].
1.2. Pathophysiology of pancreatic enzyme release in pancreatic
cancer
The physiologic biphasic pattern of pancreatic enzyme release
is lost in patients with pancreatic cancer, as shown by Ihse et al. A
standard meal (Lundh test) prompted only a small peak or no peak
in intraduodenal enzyme activity followed by a low plateau phase
in 25 patients with pancreatic cancer [13]. Similar ﬁndings were
demonstrated also in patients with chronic pancreatitis [13,14]. The
bicarbonate secretion was decreased as well [15–18].
To our knowledge no pancreatic exocrine secretion studies were
done in patients following pancreaticoduodenectomy (PD). How-
ever, one can speculate that a duodenal resection, which is the
strongest pancreatic exocrine stimulator, further contributes to
decreased postprandial pancreatic enzyme secretion in patients
with pancreatic pathology.It is also known that decreased pancreatic exocrine secretion
shifts the site of maximal nutrient absorption from the proxi-
mal  to the distal small intestine. Layer et al. demonstrated in
patients with severe PEI due to chronic pancreatitis that, following
 rights reserved.
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 standard meal, 40% of nutrients were delivered to the termi-
al ileum whereas only 5% were physiologically malabsorbed in
ealthy volunteers [19]. In addition, the authors demonstrated that
oth gastroduodenal and small intestinal transit are accelerated in
atients with PEI, which further increases the exposure of the dis-
al ileum to nutrients [19]. Consequently, we can assume that in
atients with PEI, pancreatic exocrine secretion is further dimin-
shed by a supraphysiologic nutrient exposure of the distal ileum
riggering the above mentioned feedback mechanism, which might
lso affect patients with non-surgically and surgically treated pan-
reatic cancer.
. PEI in pancreatic cancer
Despite an estimated incidence of 46,420 pancreatic cancer
ases in 2014 in the US, the treatment of pancreatic cancer is often
estricted to the oncological aspect whereas PEI is commonly dis-
egarded in this cohort [20]. As of now, several mechanisms of PEI
ave been described in the context of pancreatic cancer. Pancreatic
trophy secondary to tumour-induced pancreatic duct obstruction
nd pancreatic ﬁbrosis can lead to preoperative PEI whereas reduc-
ion of glandular tissue following pancreatic resection, impending
ostoperative pancreatic duct occlusion, extensive denervation fol-
owing lymph node dissection, and surgically altered anatomy
ontribute further to PEI postoperatively [21].
.1. PEI in patients with inoperable pancreatic cancer
Early studies by DiMagno et al. demonstrated a lower trypsin,
ipase, and bicarbonate secretion following CCK stimulation in 17
atients with non-resected pancreatic cancer and a pancreatic duct
bstruction of 60% or more of its length [22]. Generally, a high
revalence of PEI in patients with unresectable pancreatic can-
er was demonstrated in several studies. Perez et al. detected PEI
n 75% of cases utilizing a 72-h faecal fat test, and Partelli et al.
emonstrated extreme PEI (FE1 ≤20 g/g) in 25%, severe PEI (FE1
0–100 g/g) in 14%, and moderate PEI (FE1 100–200 g/g) in
1% [23,24]. Lower FE1 level was more frequently diagnosed in
atients with pancreatic head cancer, jaundice, and clinical steator-
hea [23,24]. Acknowledging a high prevalence of PEI in this patient
ohort, Sikkens et al. prospectively assessed the incidence of PEI in
2 patients with unresectable cancer of the pancreatic head [25].
ased on FE1 testing, 67% of patients had PEI at the time of pancre-
tic cancer diagnosis and 89% at the 2-month follow-up (median)
25].
These data indicate that PEI is common and progressive in unre-
ectable pancreatic cancer, with a prevalence of 50–100%.
.2. PEI in patients with resectable pancreatic cancer
Twenty percent of patients with pancreatic cancer undergo
ancreatic resection with curative intent. Depending on the
ancer location and extent, the PD (Whipple procedure), pylorus-
reserving PD (PPPD), distal pancreatectomy (DP), or total
ancreatectomy (TP) is offered. The majority of studies analysing
EI in patients with pancreatic cancer focused either on the peri-
perative and postoperative period or on a comparison between
ifferent surgical resection methods. However, most studies were
iased by a very heterogeneous patient cohort that most of the
ime included a larger proportion of patients with benign pancre-
tic pathology and cystic neoplasms in relation to patients with
ancreatic cancer..2.1. PEI before and after pancreatic cancer surgery
Several studies addressed the prevalence of PEI prior to and after
ancreatic surgery. Utilizing the secretin stimulation test as the Disease 47 (2015) 1013–1020
gold standard, Kato et al. detected PEI in 93% of 14 consecutive
patients prior to PD, including 11 patients with pancreatic cancer
[26]. Patients with obstructive jaundice tended to have more severe
PEI. In comparison with the gold standard, 13C-labelled Trioctanoin
breath assay showed similar sensitivity for PEI; however, sensi-
tivities of parallel tested para-aminobenzoic acid (PABA) excretion
and faecal chymotrypsin dropped to 67% and 64%, respectively [26].
Comparable numbers were published by other groups. Sato et al.
preoperatively detected PEI in 46% based on PABA (44 patients,
including 11 with pancreatic cancer and 7 with ampullary adeno-
carcinoma), and Matsumoto et al. detected PEI with FE1 in 68% of
patients with pancreatic cancer (31 patients), including 42% of cases
of severe PEI (FE1 <100 g/g) [27,28].
Postoperatively, the prevalence of PEI increased from 46% to
75% at 2 months in Sato et al.’s study (11 PD, 29 PPPD) and per-
sisted in all patients with preoperative pancreatic duct diameter
≥10 mm (n = 3) at 12 months [27]. Matsumoto et al. only reported
a signiﬁcant drop of FE1 in patients with normal preoperative FE1,
whereas low preoperative FE1 levels remained unchanged at the 1-
and 2-year postoperative follow-ups (171 PPPD, 11 PD) [28]. These
results were limited, however, by a substantial patient dropout
[28]. Focusing on the postoperative long-term outcome, Nordback
et al. detected PEI with FE1 in all patients with pancreatic cancer at a
median follow-up of 52 months (pancreatic cancer in 6/26 patients,
6 PD, 15 PPPD, 5 duodenum-preserving pancreatic head resection
[DPPHR]), although this study was  limited as the majority (n = 20)
of patients had chronic pancreatitis and cystic neoplasms [29].
In contrast, a signiﬁcant postoperative improvement of pancre-
atic exocrine function was documented by Kodama et al., though
only in ampullary cancer following PD (n = 25). Urinary PABA excre-
tion rose from 35% prior to surgery (n = 9) and 34% at 2 months
(n = 25) to 72.9% (n = 8) at 12 months postoperatively, yielding the
same level as a healthy control group (72.7%) [30]. Tanaka et al. con-
ﬁrmed these ﬁndings, yet again the study was limited to patients
with ampullary cancer [31]. The authors speculated that pancreatic
duct obstruction was  the culprit of PEI which resolved postopera-
tively in patients with ampullary cancer [30,31]. Whether these
data can be extrapolated to patients with pancreatic cancer remains
unclear.
2.2.2. PEI following PD versus PPPD for pancreatic cancer
Yamaguchi et al. compared postoperative prevalence of PEI in
patients undergoing PD (n = 10) and PPPD (n = 44) [32]. Patients
in the PD cohort had mostly pancreatic cancer, ampullary cancer
and cystic neoplasms, whereas only half of PPPD were performed
for pancreatic malignancy. Within 3 months postoperatively, mean
PABA excretion decreased in both cohorts from 61.6% to 41.3% and
69% to 48.8%, respectively. Eventually, PABA excretion rose to 64.1%
in the PPPD cohort, but remained low in the PD cohort at 6 months.
These results were also limited by a substantial patient dropout
(Fig. 1) [32].
2.2.3. PEI following pancreatic cancer resection utilizing
pancreaticojejunostomy versus pancreaticogastrostomy
Pancreaticojejunostomy is the most common pancreaticoen-
teric anastomosis followed by pancreaticogastrostomy in the
setting of PD and PPPD [33,34]. The initial study by Lemaire et al.
detected PEI in 94% of patients based on a 72-h faecal fat excre-
tion (median 28 g/24 h) and in 100% of patients based on FE1 at 32
months (median) following PD with pancreaticogastrostomy (14
benign pancreatic tumours, 5 pancreatic cancer) [35]. Nakamura
et al. found PEI utilizing 13C-labelled mixed triglyceride breath test-
ing in 62.3% of 61 patients with a pancreaticogastrostomy following
PPPD or PD (including 8 pancreatic cancer, 10 biliary cancer, 13
ampullary cancer, and 24 cystic neoplasms) with a postoperative
follow-up range of 3–108 months [36]. Lastly, Jang et al. compared
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Fig. 1. Pancreaticoduodenectomy (Whipple procedure) (A) and pylorus-preserving pancreaticoduodenectomy (B). Patients with resectable pancreatic head cancer typically
undergo the Whipple procedure or the pylorus-preserving pancreaticoduodenectomy. Both procedures are associated with pancreatic exocrine insufﬁciency (PEI). Beside
the  reduction of pancreatic parenchyma several mechanisms contributing to PEI have been proposed. Firstly, a derangement of antral grinding in combination with a distant
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f  branches of the vagus nerve connections causing altered gastric empting and de
ain  production site of the two  important exocrine pancreatic stimulants Secretin 
he prevalence of PEI in 20 patients undergoing pancreaticoje-
unostomy with 14 patients undergoing pancreaticogastrostomy in
he setting of PPPD (10 pancreatic cancer, 17 cholangiocarcinoma)
37]. Based on FE1 testing, 95% patients in the pancreaticojejunos-
omy cohort and 100% in the pancreaticogastrostomy cohort had
EI at 21.9 and 26.5 months, respectively, although most patients
emained asymptomatic [37].
.2.4. PEI following DP for pancreatic cancer
Speicher et al. studied 83 patients following DP with FE1 test-
ng (56% pancreatic cystic neoplasms, 12% pancreatic cancer) [38].
reoperatively, 30% patients with pancreatic cancer and 66% with
hronic pancreatitis were diagnosed with PEI. Postoperatively,
atients with normal preoperative FE1 only developed PEI when
he resection extended to the right of the portal vein (12% at 3-
onth and 8% at 12-month follow-up). None of the patients had
EI at the 24-month follow-up. A subgroup analysis for pancreatic
ancer was, however, not performed [38].
.2.5. PEI following PD and PPPD versus DP for pancreatic cancer
Differences of PEI magnitude and prevalence between pancre-
tic head and pancreatic tail resections were pointed out in several
ohort studies. Sato et al. detected a signiﬁcant drop in PABA
xcretion in all patients following PPPD (27 patients, including 7
ancreatic cancer and 5 ampullary cancer) from 72.9% preoperative
o 47.3% 2 months postoperative [39]. In contrast, no signiﬁcant
hange in PABA excretion was reported in the DP cohort (n = 12)
39]. Similarly, Sikkens et al. reported a postoperative rise in the
revalence of PEI based on FE1 testing from 42% to 92% at 6
onths (PPPD [n = 24] and PD [n = 2]), whereas the prevalence of
EI remained unchanged in the DP (n = 3) cohort at 66% [40]. Of
ote, this study included only patients with malignant tumours
pancreatic head [n = 9], body or tail [n = 3], ampullary [n = 14], and
istal common bile duct [n = 3]) [40]. The higher postoperative
EI prevalence following pancreatic head resection versus DP was
lso delineated by Yuasa et al. in 110 patients who underwent
D (n = 10), PPPD (n = 70), and DP (n = 30) for intraductal papil-
ary mucinous neoplasm (IPMN, n = 30), pancreatic cancer (n = 26),
mpullary cancer (n = 15), and cholangiocarcinoma (n = 10) [41].
ased on 13C-labelled mixed triglyceride breath test at 17 months
median) postoperative, 64% of patients had PEI in the pancreatic
ead resection cohort (PD and PPPD) and 30% in the DP cohort
n = 30) [41].ondly, lymph node dissection and transection of the duodenum result in disruption
d pancreatic exocrine function. Lastly, the resection of the duodenum which is the
CK, results in declined pancreatic exocrine function.
2.2.6. Summary of PEI following pancreatic resection for
pancreatic cancer and limitations of available data
In summary, the available data indicate that PEI occurs in
46–100% of patients with resectable pancreatic cancer. Following
PD and PPPD prevalence of PEI remains high at a rate of 70–100%,
irrespective of whether patients undergo PD or PPPD and whether a
pancreaticogastrostomy or pancreaticojejunostomy is performed.
A lower prevalence of PEI (30–66%) is found in patients with DP,
which can be explained by preservation of the duodenum. Whether
patients with pancreatic cancer experience long term improvement
of pancreatic exocrine function following pancreatic surgery can-
not be drawn at that point. These conclusions are limited by the
heterogeneous and small cohorts, as well as the utilization of non-
gold standard testing for PEI. A substantial limitation of FE1 as a
non-gold standard test for PEI is highlighted in two recent stud-
ies which challenge the results of previously outlined publications.
Halloran et al. found no correlation between the 72-h faecal fat
excretion test and FE1 testing in 40 patients with pancreatic can-
cer, ampullary carcinoma, and cholangiocarcinoma following PPPD
(n = 21), PD (n = 16), and DP (n = 3) for which the authors questioned
the reproducibility and accuracy of FE1 testing in postoperative
patients [42]. Benini et al. tested parallel 72-h faecal fat excre-
tion and FE1in 42 patients with conservatively managed chronic
pancreatitis and cystic ﬁbrosis and in 40 patients following PPPD
(n = 37), PD (n = 1), or TP (n = 2) for cystic neoplasms (n = 25), pan-
creatic cancer (n = 8), and neuroendocrine tumour (n = 4) [43]. The
authors demonstrated good correlation between both tests only
in conservatively managed patients, with FE1 <100 g/g achieving
sensitivity and speciﬁcity of 93.3% and 81.5% respectively. How-
ever, in agreement with Halloran et al., FE1 did not correlate with
the 72-h faecal fat assay in postoperative patients. The authors
suspected that small bowel bacterial overgrowth, derangement of
antral grinding, and poor mixing of digestive enzymes with chyme
in postoperative anatomy cause PEI-independent steatorrhea [43].
These ﬁndings indicate to avoid FE1 and faecal chymotrypsin assays
for postoperative assessment of steatorrhea.
3. Symptoms and quality of life in patient with pancreatic
cancer and PEIIt is a common assumption that severe PEI is always associated
with dyspepsia and steatorrhea as a result of fat malabsorption.
This is based on early studies of DiMagno et al. demonstrating that
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ild PEI with subtle changes on pancreatic function tests resulted
n no signiﬁcant clinical symptoms, whereas severe PEI, with loss of
0% of pancreatic exocrine function in chronic pancreatitis, caused
aldigestion of fat and protein leading to dyspepsia and steator-
hea [44]. However, more recent studies of unresectable pancreatic
ancer, including two trials with 12 and 194 patients, respectively,
ound no statistically signiﬁcant correlation between subjective
teatorrhea and the presence of fat malabsorption veriﬁed by stool
esting [23,24]. In fact, only 16.7% of patients with very severe
EI had clinically evident steatorrhea in one trial. Whereas 5.2%
f patients had subjective steatorrhea without objective PEI [24].
Similar ﬁndings were described in the postoperative setting.
eoptolemos et al. detected PEI with 72-h faecal fat testing in 56%
f patients following PD (n = 11), PPPD (n = 6), DPPHR (n = 5), DP
n = 7), necrosectomy (n = 4), and TP (n = 6), though the aetiology of
ancreatic disease was not disclosed in this study [45]. The pres-
nce of PEI did not correlate with dyspepsia, only with stool volume
nd frequency. Of note, 60% of patients with a faecal fat content
15 g/24 h had no or only mild dyspepsia [45]. Also, Traverso et al.
eported no dyspepsia in 7 out of 8 patients following PPPD (1 duo-
enal cancer, 1 pancreatic cancer, 8 chronic pancreatitis) despite
he presence of severe PEI based on a 72-h faecal fat assay (mean
4 g/24 h) [46]. Altogether, these results demonstrate a lack of cor-
elation between dyspepsia and PEI both in non-surgical patients
ith pancreatic cancer and patients following pancreatic surgery
23,24,45,46].
Weight loss is a well-known problem of patients with pancreatic
ancer who do not qualify for curative resection, and furthermore,
t is often the herald of the terminal disease stage. Yet, postopera-
ive weight loss was also reported by multiple authors. van Berge
enegouwen et al. reported a mean body weight loss, in relation
o the baseline body weight, of 7% following pancreatic cancer
iagnosis and 15% at the 3-month postoperative follow-up in 125
atients who underwent PD (n = 56) and PPPD (n = 69) [47]. Huang
t al. found a similar range of postoperative weight loss, averaging
4 pounds in patients with pancreatic cancer (n = 54), but only 10
ounds in patients with chronic pancreatitis (n = 34) and 1 pound in
 control cohort (laparoscopic cholecystectomy, n = 37) at a mean
ollow-up of 47 months [48]. It is unclear whether malabsorption,
ecreased caloric intake, or both are the culprit of postoperative
eight loss following pancreatic cancer surgery. In regard to non-
urgical patients with pancreatic cancer, Perez et al. proved that
nly fat and protein malabsorption, not calorie consumption, cor-
elated signiﬁcantly with weight loss [23]. Whether the data can
e extrapolated to postoperative patients with pancreatic cancer
emains unclear. In this context, a lower quality of life, which
ncludes the presence of dyspepsia and weight loss, was shown
y Halloran et al. in 40 patients following PD, PPPD, and DP for
nderlying malignancy when postoperative PEI was  present [42].
. Predictors for PEI following pancreatic surgery
The clinical impact of PEI, which was reviewed in the previous
aragraph, stresses the importance to identify patients at risk for
evelopment of postoperative PEI. Multiple authors used the pan-
reatic main duct diameter, the pancreatic glandular diameter, and
he degree of pancreatic ﬁbrosis as predictors for postoperative PEI
41]. Focusing on the main pancreatic duct diameter, Sato et al.
eported in 44 patients, including 11 with pancreatic cancer, that a
reoperative duct diameter ≥10 mm was associated with a lower
ostoperative PABA excretion at 2 months in comparison with nor-
al  preoperative duct diameter (53% versus 89%) [27]. Addressing
ostoperative pancreatic main duct dilation, Matsumoto et al. failed
o prove a correlation between postoperative duct dilation (>3 mm)
nd FE1 excretion [28]. Assuming anastomotic stricturing to be the Disease 47 (2015) 1013–1020
culprit of duct dilation in this study, the authors concluded that
a reduction of pancreatic tissue contributed more than an anasto-
motic stricture to postoperative PEI [28].
Nakamura et al. compared postoperative 13C-labelled mixed
triglyceride breath testing in 52 patients who  underwent PPPD
mainly for IPMN, ampullary cancer, pancreatic cancer, and cholan-
giocarcinoma with pancreatic parenchymal thickness on computer
tomography imaging [49]. A postoperative pancreatic parenchy-
mal  thickness cut-off of 13 mm identiﬁed PEI with a sensitivity and
speciﬁcity of 88.2% and 88.9%, respectively [49].
In contrast to PD and its variants, DP does not alter the bowel
anatomy, which implicates that postoperative changes in exocrine
pancreatic function can be mainly attributed to decreased pan-
creatic parenchyma. In this context, Speicher et al. demonstrated
that patients with normal preoperative pancreatic exocrine func-
tion developed PEI only when the DP extended to the right of the
portal vein, which reﬂects a larger resection [38]. Additional stud-
ies conﬁrmed that the magnitude of pancreatic glandular reduction
correlates with postoperative PEI [50].
Combining both pancreatic thickness and duct diameter, Sato
et al. found a negative correlation of postoperative PABA excretion
rate following PD and PPPD (39 patients, including 7 pancreatic
cancer) and the preoperative ratio of pancreatic main duct and
parenchymal diameter at the presumed surgical transection line
on computer tomography images [39]. In summary, both dilated
pancreatic duct and diminished pancreatic parenchymal thickness
on pre- and postoperative assessment correlate with a higher rate
of postoperative PEI.
Prediction of PEI by magnetic resonance imaging and endo-
scopic ultrasound is, as of now, limited to conservatively managed
patients with chronic pancreatitis [51–54].
5. Overview of pancreatic enzyme replacement therapy for
PEI
Indication for pancreatic enzyme replacement therapy (PERT),
according to expert opinion, is progressive weight loss and
steatorrhea deﬁned as at least 7–15 g faecal fat per day on a
100 g fat per day diet [55,56]. However, there is no substantial
data to support these guidelines [55]. To achieve optimal lipid
digestion 25,000–50,000 international units (IU) of lipase (equals
75,000–150,000 United States Pharmacopoeia units [USP]) are
required for a typical meal.
It is a general assumption that effective PERT requires optimal
mixture of pancreatic enzymes and chyme as proximally as pos-
sible in order to optimize digestion. In patients who  are managed
conservatively, PERT needs to be taken during or after consumption
of the meal. The optimal timing of postoperative PERT in relation
to food intake is unclear [57,58].
A known limitation of PERT is that lipase is inactivated by gastric
acid. Therefore, with the exception of Viokace® (Pancrelipase), cur-
rent pancreatic enzyme replacement preparations consist of acid-
resistant, pH-sensitive microspheres which prevent denaturation
of lipase by gastric acid. Moreover, lipase is released from micro-
spheres at a pH of 5.5–6, which is assumed to be in the duodenum.
Current available microsphere sizes are 1–2 mm.  This is based
on studies in healthy volunteers, which revealed that sphere sizes of
1 mm emptied faster than chyme into duodenum whereas spheres
of 2.4–3.2 mm  did slower. Both extremes result in dissociation of
duodenal passage of enzymes and chyme [59–61]. By extrapolation,
optimal sphere size was calculated to be 1.4 mm [59,60].5.1. PERT in patients with inoperable pancreatic cancer
As of now, multiple studies showed improved fat absorp-
tion with pH-sensitive microsphere formulation in comparison to
M.J. Bartel et al. / Digestive and Liver Disease 47 (2015) 1013–1020 1017
Fig. 2. Pancreatic enzyme replacement therapy in patients with unresectable pancreatic cancer. Patients without evidence of pancreatic duct obstruction are at risk for
pancreatic exocrine insufﬁciency (PEI). PEI should be assessed with faecal chymotrypsin or FE1 in lieu of a 72-h faecal fat assay. A diagnosis of PEI warrants initiation of
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cancreatic enzyme replacement therapy (PERT), irrespective of the presence or abse
EI  can be assumed in practically all patients warranting initiation of PERT.
onventional pancreatic enzyme preparations or placebo in
atients with chronic pancreatitis and PEI [62–68]. However, only
 few studies addressed the utility of PERT for patients with inoper-
ble pancreatic cancer. Bruno et al. randomly assigned 21 patients
ith pancreatic cancer following endoscopic biliary decompres-
ion into a placebo or PERT group. All patients experienced weight
oss prior to the randomization [69]. At 4 weeks, patients in the
ERT group (n = 11) regained 1.2% of their body weight, whereas
atients in the placebo group (n = 10) lost 3.7% [69]. More recently,
omínguez-Mun˜oz et al. presented a retrospective, not random-
zed case series of 76 patients with inoperable pancreatic cancer
70]. The patients received either Creon® (Pancrelipase) replace-
ent with nutritional counselling and palliative care (n = 45) or
tandard palliative care without PERT (n = 21). Although measure-
ent of PEI was not mentioned in this study along with absence of
andomization of treatment, the median survival of patients with
ERT was longer than the survival of patient with standard pallia-
ive therapy alone (301 days versus 89 days) [70].
An important limitation of previous studies that have addressed
ERT is the not well understood gastric empting kinetics in patients
ith conservatively managed pancreatic pathology. In that con-
ext no data exist for pancreatic cancer and the information is
xtrapolated from studies in chronic pancreatitis and from healthy
olunteers. Bruno et al. showed that 2 mm  spheres emptied faster
nto the duodenum than a radioactive labelled solid meal in patients
ith chronic pancreatitis (50th percentile 24 min  versus 52 min).
f note, the empting rate into the duodenum in healthy volunteers
howed opposing results (50th percentile 172 min  and 77 min) [71].
n conjunction with these results, Domínguez-Mun˜oz et al. ana-
ysed the timing of PERT in relation to food intake in patients with
hronic pancreatitis and documented PEI. Utilizing 13C-labelled
ixed triglyceride breath test, PERT given along with or following
ood intake resulted in better fat absorption than PERT administra-
ion before food intake, although the ﬁndings were not signiﬁcant
57]. These results are in agreement with current PERT guidelines
n conservatively managed pancreatic conditions in terms of timing
f PERT administration in relation to food intake [1,55,72]. Similar
tudies do not exist for patients with inoperable pancreatic cancer
nd postoperative patients.
In summary, the available studies indicate that PEI is present
n more than 50% of patients with inoperable pancreatic cancer.
urther, PEI appears not to correlate with the presence of clini-
ally evident steatorrhea. Obstruction of the pancreatic duct is not
niversally present in patients with unresectable pancreatic can-
er. However, Bruno et al.’s results indicate that this subgroup off subjective PEI symptoms. In patients with evidence of pancreatic duct obstruction
patients with pancreatic cancer can beneﬁt from PERT in terms of
a decelerated weight loss (Fig. 2) [69].
5.2. PERT in patients following PD
Data on the utility of PERT for PEI following surgery for pan-
creatic cancer are limited as well. Braga et al. induced complete
PEI by occluding the pancreatic duct with Neoprene following PD
for mostly malignant conditions [73]. Although patients regained
weight on PERT, they remained on average 7% under the preop-
erative weight. In addition, they had an elevated mean faecal fat
excretion (10.7 g/24 h) at 2.5 years [73]. Even higher rates of steat-
orrhea and postoperative weight loss were reported in a recent
study by Sikkens et al. Despite PERT in 37 patients with pancreatic
cancer following PD (84%), 68% of patients had subjective steat-
orrhea and 46% of patients reported further weight loss [74]. The
same authors demonstrated a comparable rate of subjective steat-
orrhea (40%) in 29 patients with mostly pancreatic cancer following
PPPD (n = 24), PD (n = 2), and DP (n = 3) on PERT, although the BMI
remained stable in this cohort between diagnosis and the 6-month
follow-up [40]. These results were also conﬁrmed by Huang et al.
who reported abdominal pain in 41% of patients and presence of
foul stools in 59% of patients on PERT for PEI following PPPD (80%)
or PD (20%) for pancreatic cancer [48].
In summary, the limited data of patients with pancreatic can-
cer who  underwent PD reveal persistence of subject steatorrhea in
40–68% of cases while receiving PERT. The body weight appears to
stabilize on PERT postoperatively, although data from controlled
studies are lacking (Fig. 3).
Whether a change in gastric empting kinetics following pan-
creatic surgery alters the efﬁcacy of PERT is currently unclear.
Most available studies addressed acute postoperative gastric empt-
ing changes, but long term changes are underreported [75–77]. In
this context, Patti et al. measured gastric empting in 10 patients
1–45 months post-PPPD for underlying malignancies [78]. Follow-
ing PPPD, gastric empting was normal in 6 patients, rapid in 3,
and delayed in 1 [78]. The difference in gastric empting follow-
ing duodenectomy emphasizes the difﬁculty to achieve optimal
synchronous release of PERT and chyme into the small bowel.
This was also addressed by Bruno et al. who compared effec-
tiveness of PERT in patients with PEI following PD (n = 7) or
PPPD (n = 5) for pancreatic, biliary, or duodenal cancer [79]. Based
on 14C-labelled octanoate breath test and PABA excretion, PERT
improved PEI in patients after PD to a greater extent than after
PPPD [79]. Moreover, the authors found that pancreatic enzymes
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Fig. 3. Pancreatic enzyme replacement therapy in patients following resection of
pancreatic cancer. Patients following pancreatic resection are at risk for pancreatic
exocrine insufﬁciency (PEI), with a higher risk following pancreaticoduodenectomy
versus distal pancreatectomy. Surgically altered anatomy, alterations of digestive
hormones and disruption of nerve connections result in PEI despite signiﬁcant
remaining pancreatic parenchyma. In that case, PEI should be assessed with a 72-h
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PERT) in case of PEI diagnosis, irrespective of the presence or absence of subjective
EI  symptoms.
nd solid food were released asynchronously into the jejunum only
n patients after PPPD due to a prolonged gastric empting time of
ancreatic enzyme microspheres [79].
Based on the limited data, the optimal timing and formulation
f PERT administration in relation to food intake post-PD and PPPD
emains unknown.
. Randomized controlled trials of PERT in patients with
ancreatic cancer
Given the mixed results of PERT for PEI following PD in
ncontrolled studies, randomized controlled trials are required
o evaluate efﬁciency and optimal administration of PERT. The
nly placebo-controlled, randomized trial addressing PERT that
ncluded patients with pancreatic cancer was published by Seiler
t al. [80] The authors randomized 58 patients with severe PEI based
n faecal fat testing, including 14 patients with pancreatic cancer,
nto a PERT (n = 32) or a placebo (n = 26) group 6 months following
D or PPPD (n = 29), DPPHR (n = 13), and other procedures (n = 12).
n patients with underlying malignancy fat absorption improved
ith PERT from 54.8% to 69.4% whereas fat absorption decreased
n the placebo group from 62.7% to 46.3%. Additionally, patients on
ERT reported less frequent bowel movements; however, surpris-
ngly, they had more adverse events, with ﬂatulence being the most
ommon one [80].
Similar ﬁndings were shown in several placebo-controlled,
andomized trials of PERT for patients with chronic alcoholic
ancreatitis who were treated conservatively or who underwent
rainage procedures. Improvement, but incomplete resolution of
ubjective and objective steatorrhea was reported. In addition,
ERT also had a higher incidence of adverse drug reactions like pain,
yspepsia, and ﬂatulence [81–84].
.1. Safety of PERT
Hyperuricosuria and especially colonic ﬁbrosis are well
escribed adverse drug reactions of long-term PERT, although lim-
ted to the paediatric literature in patients with cystic ﬁbrosis
85–87]. Only few data exist on the prevalence of adverse out-
omes of long-term PERT in adults. Gullo et al. reported 227 patients
ith chronic pancreatitis who received PERT from porcine pancre-
tic extract with a pH-sensitive polymer packed in gelatin capsules
88]. Ten capsules were administered daily, which reﬂects a dose of
35,000 USP units lipase and 105,000 USP units amylase. At a mean
ollow-up of 20.2 months, no adverse events were recorded beyond
[ Disease 47 (2015) 1013–1020
occasional dyspepsia and heartburn. Fifteen patients who received
PERT for 4 years had normal colonic thickness by ultrasound [88].
Most recent, open-labelled PERT trials lasting for 6–12 months did
not report signiﬁcant adverse drug reactions either [89,90].
7. Conclusion
Most of the current knowledge of pancreatic enzyme physiology
relies on studies performed in healthy volunteers and patients with
chronic pancreatitis. Available data on patients with pancreatic
cancer suggest presence of fat malabsorption in a high proportion
of patients at the time of the diagnosis. Progression of pancreatic
cancer and pancreatic cancer surgery can additionally aggravate
PEI.
PERT is the standard of care in patients with PEI in the setting
of chronic pancreatitis. Studies that included non-surgical candi-
dates and postoperative patients with pancreatic cancer tended to
show an improvement of both subjective symptoms, like dyspep-
sia, as well as objective ﬁndings, including body weight and faecal
fat excretion, with PERT. Conﬁrmatory studies with randomized
controlled protocols are paramount, but currently not available.
New oncologic protocols (e.g., FOLFIRINOX) improved the survival
of patients with pancreatic cancer. In this context, the optimization
of the performance status of patients with pancreatic cancer is of
the highest importance in order to make those patients eligible for
new adjuvant or palliative options. We  suspect that PERT plays a
role here, but conﬁrmatory studies are required. Further studies are
required to determine optimal dose and timing of PERT in relation
to meals in patients following PD.
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